In conclusion, this study demonstrated, for the first time, that CRTAC1 promotes cisplatin-dependent apoptosis in NSCLC and is a potential tumor molecular marker for predicting and improving cisplatin sensitivity in patients with NSCLC. Here, CRTAC1 is linked to neoplasm.